PL3325623T3 - Zastosowanie skojarzenia cząsteczki dbait i inhibitorów parp do leczenia nowotworu - Google Patents
Zastosowanie skojarzenia cząsteczki dbait i inhibitorów parp do leczenia nowotworuInfo
- Publication number
- PL3325623T3 PL3325623T3 PL16744699T PL16744699T PL3325623T3 PL 3325623 T3 PL3325623 T3 PL 3325623T3 PL 16744699 T PL16744699 T PL 16744699T PL 16744699 T PL16744699 T PL 16744699T PL 3325623 T3 PL3325623 T3 PL 3325623T3
- Authority
- PL
- Poland
- Prior art keywords
- combination
- treat cancer
- parp inhibitors
- dbait molecule
- dbait
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/13—Decoys
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15306201 | 2015-07-23 | ||
EP16166674 | 2016-04-22 | ||
PCT/EP2016/067479 WO2017013237A1 (en) | 2015-07-23 | 2016-07-22 | Use of a combination of dbait molecule and parp inhibitors to treat cancer |
EP16744699.6A EP3325623B3 (en) | 2015-07-23 | 2016-07-22 | Use of a combination of dbait molecule and parp inhibitors to treat cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
PL3325623T3 true PL3325623T3 (pl) | 2019-12-31 |
PL3325623T6 PL3325623T6 (pl) | 2022-05-30 |
Family
ID=56551383
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL16744699T PL3325623T6 (pl) | 2015-07-23 | 2016-07-22 | Zastosowanie skojarzenia cząsteczki dbait i inhibitorów parp do leczenia nowotworu |
Country Status (17)
Country | Link |
---|---|
US (2) | US10563197B2 (pl) |
EP (2) | EP3325623B3 (pl) |
JP (1) | JP6457696B2 (pl) |
KR (1) | KR101896567B1 (pl) |
CN (1) | CN108138177B9 (pl) |
AU (1) | AU2016296905B2 (pl) |
CA (1) | CA2993270C (pl) |
DK (2) | DK3594343T3 (pl) |
ES (2) | ES2879434T3 (pl) |
HK (1) | HK1248281B (pl) |
HU (1) | HUE045916T2 (pl) |
IL (1) | IL256799A (pl) |
LT (1) | LT3325623T (pl) |
PL (1) | PL3325623T6 (pl) |
PT (1) | PT3325623T (pl) |
SI (1) | SI3325623T1 (pl) |
WO (1) | WO2017013237A1 (pl) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201709076D0 (en) * | 2017-06-07 | 2017-07-19 | Inst Of Cancer Research: Royal Cancer Hospital | Parp inhibitors for use in methods of treating cancer |
EP3461488A1 (en) * | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dbait molecule and a hdac inhibitor for treating cancer |
CA3092779A1 (en) * | 2018-03-13 | 2019-09-19 | Onxeo | A dbait molecule against acquired resistance in the treatment of cancer |
JP7450622B2 (ja) * | 2018-12-21 | 2024-03-15 | ヴァレリオ・セラピューティクス | 新規のコンジュゲートされた核酸分子及びその使用 |
MX2021009863A (es) * | 2019-03-21 | 2021-11-12 | Onxeo | Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer. |
CN114173781A (zh) * | 2019-03-25 | 2022-03-11 | 赛泰尔治疗公司 | Rad51和parp抑制剂的组合 |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
AR122644A1 (es) | 2020-06-19 | 2022-09-28 | Onxeo | Nuevas moléculas de ácido nucleico conjugado y sus usos |
CA3240558A1 (en) | 2021-12-16 | 2023-06-22 | Valerio Therapeutics | New conjugated nucleic acid molecules and their uses |
Family Cites Families (120)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ234854A (en) | 1989-08-11 | 1993-02-25 | Ici Plc | Quinoline derivatives, preparation, intermediates and pharmaceutical compositions thereof |
IE903911A1 (en) | 1989-11-20 | 1991-05-22 | Ici Plc | Diazine derivatives |
CA2079109A1 (en) | 1990-03-29 | 1991-09-30 | John A. Latham | Oligonucleotide-transport agent disulfide conjugates |
EP0453210A3 (en) | 1990-04-19 | 1993-01-13 | Imperial Chemical Industries Plc | Pyridine derivatives |
US5843643A (en) | 1992-02-21 | 1998-12-01 | Ratner; Paul L. | Site-specific transfection of eukaryotic cells using polypeptide-linked recombinant nucleic acid |
US5646042A (en) | 1992-08-26 | 1997-07-08 | Ribozyme Pharmaceuticals, Inc. | C-myb targeted ribozymes |
US5587384A (en) | 1994-02-04 | 1996-12-24 | The Johns Hopkins University | Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity |
GB9404485D0 (en) | 1994-03-09 | 1994-04-20 | Cancer Res Campaign Tech | Benzamide analogues |
DE4418965A1 (de) | 1994-05-31 | 1995-12-07 | Boehringer Ingelheim Int | Verfahren zum Einbringen von Nukleinsäure in höhere eukaryotische Zellen |
EP0831922A2 (en) | 1995-06-08 | 1998-04-01 | Therexsys Limited | Improved pharmaceutical compositions for gene therapy |
AUPN741696A0 (en) | 1996-01-05 | 1996-01-25 | Commonwealth Scientific And Industrial Research Organisation | Delivery of nucleic acids ii |
US6514983B1 (en) | 1997-09-03 | 2003-02-04 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage |
US6426415B1 (en) | 1997-09-03 | 2002-07-30 | Guilford Pharmaceuticals Inc. | Alkoxy-substituted compounds, methods and compositions for inhibiting parp activity |
US6291425B1 (en) | 1999-09-01 | 2001-09-18 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage |
US6635642B1 (en) | 1997-09-03 | 2003-10-21 | Guilford Pharmaceuticals Inc. | PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same |
BR9813202B1 (pt) | 1997-09-15 | 2011-11-01 | complexo de administração de genes; processo de transdução de células com material genético estranho, composição útil para administração de material genético e uso de um complexo de administração de genes. | |
US7635722B1 (en) | 1998-07-27 | 2009-12-22 | Saint Jude Pharmaceuticals, Inc. | Chemical induced intracellular hyperthermia |
PL210415B1 (pl) | 1999-01-11 | 2012-01-31 | Agouron Pharma | Pochodne indolu, środek farmaceutyczny i zastosowanie pochodnych indolu |
EP1142881A4 (en) | 1999-01-14 | 2003-05-07 | Meiji Seika Kaisha | POLY (ADP-RIBOSE) POLYMERASE INHIBITORS CONSISTING OF PYRIMIDINE DERIVATIVES |
US6465448B1 (en) | 1999-08-13 | 2002-10-15 | Case Western Reserve University | Methoxyamine potentiation of temozolomide anti-cancer activity |
ECSP003637A (es) | 1999-08-31 | 2002-03-25 | Agouron Pharma | Inhibidores triciclicos de poli (adp-ribosa) polimerasas |
WO2001021615A1 (en) | 1999-09-17 | 2001-03-29 | Yamanouchi Pharmaceutical Co., Ltd. | Benzimidazole derivatives |
CN1374961A (zh) | 1999-09-28 | 2002-10-16 | 巴斯福股份公司 | 氮杂䓬吲哚衍生物,它们的制备和应用 |
US6476048B1 (en) | 1999-12-07 | 2002-11-05 | Inotek Pharamaceuticals Corporation | Substituted phenanthridinones and methods of use thereof |
US6444676B1 (en) | 1999-12-20 | 2002-09-03 | Iok-Hou Pang | Use of PARP inhibitors in the treatment of glaucoma |
EP1257551B1 (de) | 2000-02-01 | 2007-09-05 | Abbott GmbH & Co. KG | Heterozyklische verbindungen und deren anwendung als parp-inhibitoren |
AU2001248748A1 (en) | 2000-04-18 | 2001-10-30 | Sumitomo Pharmaceuticals Company, Limited | Substituted piperazine compounds |
US20060276497A1 (en) | 2000-05-09 | 2006-12-07 | Cephalon, Inc. | Novel multicyclic compounds and the use thereof |
US7122679B2 (en) | 2000-05-09 | 2006-10-17 | Cephalon, Inc. | Multicyclic compounds and the use thereof |
DE10022925A1 (de) | 2000-05-11 | 2001-11-15 | Basf Ag | Substituierte Indole als PARP-Inhibitoren |
AU2001264595A1 (en) | 2000-05-19 | 2001-12-03 | Guilford Pharmaceuticals Inc. | Sulfonamide and carbamide derivatives of 6(5h)phenanthridinones and their uses |
WO2001091796A2 (en) | 2000-06-01 | 2001-12-06 | Guilford Pharmaceuticals Inc. | Methods, compounds and compositions for treating gout |
GB0017508D0 (en) | 2000-07-17 | 2000-08-30 | Novartis Ag | Antimicrobials |
US6903101B1 (en) | 2000-08-10 | 2005-06-07 | Bayer Pharmaceuticals Corporation | Substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity |
HU228960B1 (hu) | 2000-10-30 | 2013-07-29 | Kudos Pharm Ltd | Ftalazinon-származékok |
ITMI20002358A1 (it) | 2000-10-31 | 2002-05-01 | Flavio Moroni | Derivati di tieno ,2, 3-c|isochinolin-3-one come inibitori della poli(a dp-ribosio)polimerasi |
ATE478664T1 (de) | 2000-12-01 | 2010-09-15 | Eisai Inc | Azaphenanthridone-derivate und deren verwendung als parp-inhibitoren |
AU2002220241A1 (en) | 2000-12-01 | 2002-06-11 | Iconix Pharmaceuticals, Inc. | Parb inhibitors |
WO2002068407A1 (fr) | 2001-02-28 | 2002-09-06 | Yamanouchi Pharmaceutical Co., Ltd. | Compose benzimidazole |
DE60231868D1 (de) | 2001-04-24 | 2009-05-20 | Purdue Research Foundation | Folat-mimetika und deren folatrezeptorbindende konjugate |
WO2002094790A1 (fr) | 2001-05-23 | 2002-11-28 | Mitsubishi Pharma Corporation | Compose heterocyclique condense et son utilisation medicale |
JP3935363B2 (ja) | 2001-06-26 | 2007-06-20 | サカタインクス株式会社 | 水性顔料分散体の製造方法およびその方法から得られる水性顔料分散体 |
WO2003007959A1 (en) | 2001-07-16 | 2003-01-30 | Fujisawa Pharmaceutical Co., Ltd. | Quinoxaline derivatives which have parp inhibitory action |
WO2003014121A1 (en) | 2001-08-07 | 2003-02-20 | Guilford Pharmaceuticals Inc. | Compounds, derivatives, compositions, preparation and uses |
KR100957516B1 (ko) | 2001-08-15 | 2010-05-14 | 이코스 코포레이션 | 2h-프탈라진-1-온 및 이것의 사용 방법 |
US20030096833A1 (en) | 2001-08-31 | 2003-05-22 | Jagtap Prakash G. | Substituted ideno[1,2-c]isoquinoline derivatives and methods of use thereof |
WO2003051879A1 (en) | 2001-12-14 | 2003-06-26 | Altana Pharma Ag | Known and novel 4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-ones useful as poly(adp-ribose)polymerase inhibitors |
WO2003057145A2 (en) | 2001-12-31 | 2003-07-17 | Guilford Pharmaceuticals Inc. | SUBSTITUTED 4,9-DIHYDROCYCLOPENTA[imn]PHENANTHRIDINE-5-ONES DERIVATIVES THEREOF AND THEIR USES |
US7026311B2 (en) | 2002-01-10 | 2006-04-11 | Abbott Gmbh & Co., Kg | Dibenzodiazepine derivatives, their preparation and use |
AU2003277674A1 (en) | 2002-11-12 | 2004-06-03 | Mochida Pharmaceutical Co., Ltd. | Novel parp inhibitors |
AU2003284632A1 (en) | 2002-11-22 | 2004-06-18 | Mitsubishi Pharma Corporation | Isoquinoline compounds and medicinal use thereof |
BRPI0408284B8 (pt) | 2003-03-12 | 2021-05-25 | Kudos Pharm Ltd | compostos derivados de ftalazinona, seu uso e composição farmacêutica compreendendo os mesmos |
WO2004087713A1 (en) | 2003-03-31 | 2004-10-14 | Pfizer Inc. | Salts of tricyclic inhibitors of poly(adp-ribose) polymerases |
HU227948B1 (en) | 2003-04-30 | 2012-07-30 | Pecsi Tudomanyegyetem | Quinazoline derivatives and their use for the preparation of pharmaceutical compositions inhibiting parp enzyme |
JP4824566B2 (ja) | 2003-05-28 | 2011-11-30 | エーザイ インコーポレーテッド | Parpを阻害するための化合物、方法、および医薬組成物 |
WO2004108723A1 (en) | 2003-06-04 | 2004-12-16 | Altana Pharma Ag | 4,5-dihydro-imidazo[4,5,1-ii]quinolin-6-ones as parp inhibitors |
US7531530B2 (en) | 2003-07-25 | 2009-05-12 | Cancer Research Technology Limited | Therapeutic compounds |
MXPA06002513A (es) | 2003-09-04 | 2006-06-20 | Warner Lambert Co | Benzo[b]tiofenos halo-sustituidos con actividad inhibidora de fosfoinositido-3-cinasas (pi3k) como agentes terapeuticos. |
AU2004270187A1 (en) | 2003-09-04 | 2005-03-17 | Aventis Pharmaceuticals Inc. | Substituted indoles as inhibitors of poly (ADP-ribose) polymerase (PARP) |
EP1526177A1 (en) | 2003-10-24 | 2005-04-27 | Institut Curie | Nucleic acids useful for triggering tumor cell lethality |
US7476729B2 (en) * | 2003-10-24 | 2009-01-13 | Institut Curie | Dbait and uses thereof |
SG150533A1 (en) | 2003-11-20 | 2009-03-30 | Janssen Pharmaceutica Nv | 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2- quinoxalinones as poly(adp-ribose) polymerase inhibitors |
NZ546990A (en) | 2003-11-20 | 2010-03-26 | Janssen Pharmaceutica Nv | 7-Phenylalkyl substituted 2-quinolinones and 2 quinoxalinones as poly(adp-ribose) polymerase inhibitors |
UA89618C2 (ru) | 2003-12-05 | 2010-02-25 | Янссен Фармацевтика Н.В. | 6-замещенные 2-хинолиноны и 2-хиноксалиноны как ингибиторы поли(адф-рибоза)полимеразы |
KR101149031B1 (ko) | 2003-12-10 | 2012-05-29 | 얀센 파마슈티카 엔.브이. | 폴리(adp-리보스)폴리머라제 저해제로서의 치환된6-사이클로헥실알킬 치환된 2-퀴놀리논 및 2-퀴녹살리논 |
DE202004003061U1 (de) | 2004-02-25 | 2005-07-14 | Kronospan Technical Company Ltd., Engomi | Dekorpapier mit elektrisch geladenen Fasern |
PE20060285A1 (es) | 2004-03-30 | 2006-05-08 | Aventis Pharma Inc | Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp) |
WO2005108400A1 (ja) | 2004-05-11 | 2005-11-17 | Mochida Pharmaceutical Co. Ltd. | 二環系へテロ環で置換されたピリドキナゾリン誘導体 |
WO2005112935A1 (en) | 2004-05-13 | 2005-12-01 | Vanderbilt University | Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis |
DE102004028973A1 (de) | 2004-06-16 | 2006-01-05 | Sanofi-Aventis Deutschland Gmbh | Substituierte Tetrahydro-2H-isochinolin-1-on-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament |
CA2568835C (en) | 2004-06-30 | 2014-05-27 | Janssen Pharmaceutica N.V. | Quinazolinone derivatives as parp inhibitors |
AU2005259189B2 (en) | 2004-06-30 | 2011-04-21 | Janssen Pharmaceutica N.V. | Phthalazine derivatives as PARP inhibitors |
MXPA06014541A (es) | 2004-06-30 | 2007-03-23 | Janssen Pharmaceutica Nv | Derivados de quinazolindiona como inhibidores de la poli(adp-ribosa) polimerasa. |
EP1768674A1 (en) | 2004-07-16 | 2007-04-04 | ProteoSys AG | Muscarinic antagonists with parp and sir modulating activity as cytoprotective agents |
WO2007040469A2 (en) | 2005-09-15 | 2007-04-12 | Kosak Ken M | Chloroquine coupled compositions and methods for their synthesis |
WO2006033007A2 (en) | 2004-09-22 | 2006-03-30 | Pfizer Inc. | Polymorphic and amorphous forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one |
ES2337275T3 (es) | 2004-09-22 | 2010-04-22 | Pfizer, Inc. | Procedimiento de preparacion de inhidores de poli(adp-ribosa)-polimrerasas. |
RU2361592C2 (ru) | 2004-09-22 | 2009-07-20 | Пфайзер Инк. | Терапевтические комбинации, содержащие ингибитор поли(адф-рибоза)полимеразы |
DE102004050196A1 (de) | 2004-10-15 | 2006-04-20 | Sanofi-Aventis Deutschland Gmbh | Substituierte 2-Pyridon-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament |
GB0423653D0 (en) | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
EP1814544A4 (en) | 2004-11-05 | 2009-12-02 | Cephalon Inc | CANCER TREATMENTS |
AU2005316312B2 (en) | 2004-12-17 | 2009-10-22 | Amgen, Inc. | Aminopyrimidine compounds and methods of use |
JP2008526237A (ja) | 2005-01-07 | 2008-07-24 | アーキュル, インコーポレイテッド | Parpの調節のための組成物およびそのスクリーニング方法 |
US7820668B2 (en) | 2005-01-19 | 2010-10-26 | Eisai Inc. | Diazabenzo[de]anthracen-3-one compounds and methods for inhibiting PARP |
TWI375673B (en) | 2005-04-11 | 2012-11-01 | Abbott Lab | 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors |
WO2006110683A1 (en) | 2005-04-11 | 2006-10-19 | Abbott Laboratories | 2-substituted-1h-benzimidazole-4-carboxamides are parp inhibitors |
WO2006135873A2 (en) | 2005-06-10 | 2006-12-21 | Bipar Sciences, Inc. | Parp modulators and treatment of cancer |
JPWO2006137510A1 (ja) | 2005-06-24 | 2009-01-22 | 小野薬品工業株式会社 | 脳血管障害時における出血低減剤 |
JP5177429B2 (ja) | 2005-07-18 | 2013-04-03 | バイパー サイエンシズ,インコーポレイティド | 癌の治療 |
CA2623822C (en) | 2005-09-29 | 2013-11-12 | Abbott Laboratories | 1h-benzimidazole-4-carboxamides substituted with phenyl at the 2-position are potent parp inhibitors |
EP2007733B1 (en) | 2006-04-03 | 2016-05-25 | MSD Italia S.r.l. | Amide substituted indazole and benzotriazole derivatives as poly(adp-ribose)polymerase (parp) inhibitors |
GB0610680D0 (en) | 2006-05-31 | 2006-07-12 | Istituto Di Ricerche D Biolog | Therapeutic compounds |
JP2009539963A (ja) | 2006-06-15 | 2009-11-19 | クドス ファーマシューティカルズ リミテッド | Parp阻害剤 |
JP2009541217A (ja) | 2006-06-15 | 2009-11-26 | クドス ファーマシューティカルズ リミテッド | Parp阻害剤としての2−オキシベンズアミド誘導体 |
EP2041110A1 (en) | 2006-06-15 | 2009-04-01 | Kudos Pharmaceuticals Limited | 2 -oxyheteroarylamide derivatives as parp inhibitors |
WO2008015429A2 (en) | 2006-08-01 | 2008-02-07 | Sentinel Oncology Limited | Pharmaceutical compounds |
EP2061443A4 (en) | 2006-08-18 | 2013-07-24 | Arrowhead Res Corp | POLYCONJUGATE FOR IN VIVO ADMINISTRATION OF POLYNUCLEOTIDES |
EP1944369A1 (en) | 2007-01-12 | 2008-07-16 | The Centre National de la Recherche Scientifique | Dbait and its standalone uses thereof |
EP2134855A4 (en) | 2007-03-12 | 2011-01-05 | Dana Farber Cancer Inst Inc | PROGNOSIS, DIAGNOSIS AND USES IN THE TREATMENT OF FANCI CANCER AND FANCI MODULATION AGENTS |
US20100249112A1 (en) | 2007-05-25 | 2010-09-30 | Astrazeneca R&D | Combination of chk and parp inhibitors for the treatment of cancers |
DK2209375T3 (da) | 2007-10-03 | 2014-10-06 | Eisai Inc | Parp-inhibitorforbindelser, præparater og fremgangsmåder til anvendelse deraf |
WO2009063998A1 (ja) | 2007-11-14 | 2009-05-22 | Ribomic Inc. | 疎水性物質付加核酸及びその使用 |
AU2009234266B2 (en) | 2008-04-11 | 2015-08-06 | Tekmira Pharmaceuticals Corporation | Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components |
SA109300394B1 (ar) | 2008-06-19 | 2013-01-22 | ويث | ثيازوليل- وأوكسازوليل- أيزوكوينولينونات وطرق لاستخدامها |
WO2010056403A1 (en) | 2008-11-17 | 2010-05-20 | Enzon Pharmaceuticals, Inc. | Branched cationic lipids for nucleic acids delivery system |
WO2010082813A1 (en) | 2009-01-13 | 2010-07-22 | Academisch Medisch Centrum Bij De Universiteit Van Amsterdam | Method of treating cancer |
WO2010091140A1 (en) | 2009-02-04 | 2010-08-12 | Bipar Sciences, Inc. | Treatment of lung cancer with a parp inhibitor in combination with a growth factor inhibitor |
EP3689381A1 (en) * | 2010-06-22 | 2020-08-05 | Onxeo | Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates |
CN102372716A (zh) | 2010-08-09 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
CN106978480A (zh) * | 2010-09-15 | 2017-07-25 | 阿尔玛克诊断有限公司 | 用于癌症的分子诊断试验 |
CA2742342A1 (en) * | 2011-02-12 | 2012-08-12 | Baylor Research Institute | Msh3 expression status determines the responsiveness of cancer cells to the chemotherapeutic treatment with parp inhibitors and platinum drugs |
BR112013026327A2 (pt) | 2011-04-11 | 2019-09-24 | Abbvie Inc | inibidores da parp para o tratamento de neuropatia periférica induzida por quimioterapia |
EP2527440A1 (en) * | 2011-05-27 | 2012-11-28 | Institut Curie | Cancer treatment by combining DNA molecules mimicking double strand breaks with hyperthermia |
SG11201404888SA (en) * | 2012-02-17 | 2014-09-26 | Pharmacyclics Inc | Combinations of histone deacetylase inhibitor and pazopanib and uses thereof |
AU2013284487A1 (en) | 2012-06-27 | 2015-02-19 | Sunflower Research Llc | Compounds and therapeutic uses thereof |
WO2014073447A1 (ja) * | 2012-11-08 | 2014-05-15 | 日本化薬株式会社 | カンプトテシン類と抗癌効果増強剤の結合した高分子化合物及びその用途 |
CN104003979B (zh) | 2013-02-21 | 2016-08-17 | 上海汇伦生命科技有限公司 | 苯并咪唑-2-哌嗪类化合物、其药物组合物及其制备方法和用途 |
WO2014170441A1 (en) * | 2013-04-19 | 2014-10-23 | Dna Therapeutics | Inhibition of dna damage repair by artificial activation of parp with oligonucleotide molecules |
CN104140426B (zh) | 2013-05-07 | 2017-02-01 | 上海汇伦生命科技有限公司 | 嘧啶并咪唑类化合物、其药物组合物及其制备方法和用途 |
CN104230896A (zh) | 2013-06-17 | 2014-12-24 | 上海汇伦生命科技有限公司 | 苯并咪唑-2-哌嗪杂环类化合物、其药物组合物及其制备方法和用途 |
-
2016
- 2016-07-22 CN CN201680043049.2A patent/CN108138177B9/zh active Active
- 2016-07-22 CA CA2993270A patent/CA2993270C/en active Active
- 2016-07-22 EP EP16744699.6A patent/EP3325623B3/en active Active
- 2016-07-22 WO PCT/EP2016/067479 patent/WO2017013237A1/en active Application Filing
- 2016-07-22 ES ES19177392T patent/ES2879434T3/es active Active
- 2016-07-22 LT LT16744699T patent/LT3325623T/lt unknown
- 2016-07-22 KR KR1020187005307A patent/KR101896567B1/ko active IP Right Grant
- 2016-07-22 DK DK19177392.8T patent/DK3594343T3/da active
- 2016-07-22 JP JP2018502794A patent/JP6457696B2/ja active Active
- 2016-07-22 PT PT16744699T patent/PT3325623T/pt unknown
- 2016-07-22 PL PL16744699T patent/PL3325623T6/pl unknown
- 2016-07-22 SI SI201630341T patent/SI3325623T1/sl unknown
- 2016-07-22 DK DK16744699.6T patent/DK3325623T6/da active
- 2016-07-22 HU HUE16744699A patent/HUE045916T2/hu unknown
- 2016-07-22 EP EP19177392.8A patent/EP3594343B1/en active Active
- 2016-07-22 ES ES16744699T patent/ES2742197T7/es active Active
- 2016-07-22 US US15/746,806 patent/US10563197B2/en active Active
- 2016-07-22 AU AU2016296905A patent/AU2016296905B2/en active Active
-
2018
- 2018-01-09 IL IL256799A patent/IL256799A/en active IP Right Grant
- 2018-06-20 HK HK18107898.8A patent/HK1248281B/zh unknown
-
2020
- 2020-02-14 US US16/790,788 patent/US11162095B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1248281B (zh) | Dbait分子和parp抑制劑聯合用於治療癌症的用途 | |
HK1257249A1 (zh) | 使用脂質體伊立替康和parp抑制劑用於癌症治療的組合療法 | |
IL249658A0 (en) | Methods of treating cancer using tigit inhibitors and anticancer agents | |
HK1232119A1 (zh) | 用於治療癌症的檢查點抑制劑和治療劑的組合 | |
IL258900A (en) | Treatment of small cell lung cancer with a parp inhibitor | |
HK1254349A1 (zh) | 用谷氨酰胺酶抑制劑治療肺癌 | |
HK1252816A1 (zh) | Tlr8激活劑治療癌症的應用 | |
IL266182A (en) | Farensyltransferase inhibitors for use in cancer treatment methods | |
GB201505860D0 (en) | Therapeutic compositions and methods of use for treating cancer | |
IL259781A (en) | Uses of pyrimido-pyridazinones to treat cancer | |
PL3364971T3 (pl) | Heterocykliczne inhibitory PDK1 do zastosowania w leczeniu nowotworu | |
IL268722A (en) | Methods of treating cancer with farnesyl-transferase inhibitors | |
IL272473A (en) | Methods of treating cancer with farnesyltransferase inhibitors | |
HRP20191391T1 (hr) | Uporaba kombinacije dbait molekule i parp inhibitora za liječenje raka | |
GB201709076D0 (en) | Parp inhibitors for use in methods of treating cancer | |
SI3515418T1 (sl) | Uporaba zaviralcev c-MET za zdravljenje rakov, ki vsebujejo mutacije MET | |
HK1214502A1 (zh) | 用於癌症治療的 和卡培他濱的組合 | |
TWI561255B (en) | Use of umirolimus and its derivatives for treating cancer | |
GB201317373D0 (en) | Treatment and prevention of cancer |